Shares of ABIOMED, Inc. (NASDAQ:ABMD) have earned a consensus rating of “Buy” from the eleven brokerages that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $187.57.

A number of analysts have weighed in on the company. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price for the company in a report on Tuesday, November 7th. Jefferies Group LLC upped their target price on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $160.00 price target on shares of ABIOMED in a research report on Tuesday, August 29th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, August 10th. Finally, BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research report on Sunday, October 29th.

Shares of ABIOMED (NASDAQ ABMD) opened at $199.74 on Friday. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $8,831.70, a P/E ratio of 128.04, a P/E/G ratio of 2.66 and a beta of 0.23. ABIOMED has a twelve month low of $103.53 and a twelve month high of $200.00.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.16. The firm had revenue of $132.80 million during the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. ABIOMED’s quarterly revenue was up 28.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share. research analysts expect that ABIOMED will post 2.38 EPS for the current fiscal year.

In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $178.64, for a total value of $1,786,400.00. Following the sale, the vice president now directly owns 56,757 shares of the company’s stock, valued at $10,139,070.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Eric A. Md Rose sold 982 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total transaction of $142,556.94. Following the completion of the sale, the director now directly owns 13,634 shares in the company, valued at $1,979,247.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 28,628 shares of company stock worth $4,978,890. 7.00% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Huntington National Bank purchased a new position in ABIOMED in the 2nd quarter valued at about $100,000. Seven Eight Capital LP purchased a new position in ABIOMED in the 2nd quarter valued at about $100,000. Rehmann Capital Advisory Group purchased a new position in ABIOMED in the 3rd quarter valued at about $202,000. Sigma Planning Corp purchased a new position in ABIOMED in the 3rd quarter valued at about $206,000. Finally, Dorsey & Whitney Trust CO LLC purchased a new position in ABIOMED in the 3rd quarter valued at about $215,000. 90.74% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/abiomed-inc-abmd-receives-consensus-recommendation-of-buy-from-analysts/1727232.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.